Rexahn Pharmaceuticals (RNN) Set to Announce Earnings on Monday

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) will issue its Q4 2017 quarterly earnings data on Monday, February 26th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

Shares of Rexahn Pharmaceuticals (NYSEAMERICAN RNN) opened at $1.74 on Friday. The firm has a market cap of $55.19, a P/E ratio of -1.87 and a beta of -0.65. Rexahn Pharmaceuticals has a one year low of $0.38 and a one year high of $7.10.

Several research firms have commented on RNN. ValuEngine raised shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 2nd. Zacks Investment Research raised shares of Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Friday, November 10th. Finally, HC Wainwright set a $20.00 price target on shares of Rexahn Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, February 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Rexahn Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $13.75.

WARNING: This story was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Earnings History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply